Scriptaid and suberoylanilide hydroxamic acid are histone deacetylase inhibitors with potent anti-Toxoplasma gondii activity in vitro

Journal of Parasitology

Volumn 93, Issue 3, 2007, Pages 694-700

  Strobl, Jeannine S ^a   Cassell, Meredith ^a   Mitchell, Sheila M ^a,b   Reilly, Christopher M ^a   Lindsay, David S ^a,b  

^a EDWARD VIA COLLEGE OF OSTEOPATHIC MEDICINE   (United States)

^b VIRGINIA MARYLAND REGIONAL COLLEGE OF VETERINARY MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; 6 (1,3 DIOXO 1H,3H BENZO[DE]ISOQUINOLIN 2 YL) N HYDROXYHEXANAMIDE; APICIDIN; BUTYRIC ACID; HISTONE DEACETYLASE INHIBITOR; NICOTINAMIDE; VALPROIC ACID; VORINOSTAT;

DRUG; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITOR; PARASITE; PROTOZOAN;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; ENZYME INHIBITION; FIBROBLAST; HUMAN; HUMAN CELL; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; TACHYZOITE; TOXOPLASMA GONDII; TOXOPLASMOSIS;

ANIMALS; ANTIPROTOZOAL AGENTS; BUTYRATES; CATTLE; CELL LINE; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; HYDROXYLAMINES; INHIBITORY CONCENTRATION 50; NIACINAMIDE; PARASITIC SENSITIVITY TESTS; PHENYLBUTYRATES; QUINOLINES; TOXOPLASMA; VALPROIC ACID; VITAMIN B COMPLEX;

EUKARYOTA; TOXOPLASMA GONDII;

EID: 34447121292     PISSN: 00223395     EISSN: None     Source Type: Journal    
DOI: 10.1645/GE-1043R.1     Document Type: Article

References (39)

1. AHN, H.-J., S. KIM, AND H.-W. NAM. 2003. Molecular cloning of the 82-kDa heat shock protein (HSP90) of Toxoplasma gondii associated with the entry into and growth in host cells. Biochemical and Biophysical Research Communications 311: 654-659.
2. BONFIOLI, A. A., AND F. OREFICE. 2005. Toxoplasmosis. Seminars in Opthalmology 20: 129-141.
3. DARKIN-RATTRAY, S. J., A. M. GURNETT, R. W. MYERS, P. M. DULSKI, T. M. CRUMLEY, J. J. ALLOCCO, C. CANNOVA, P. T. MEINKE, S. L. COLLETTI, M. A. BEDNAREK, S. B. SINGH, M. A. GOETZ, A. W. DOMBROWSKI, J. D. POLISHOOK, AND D. M. SCHMATZ. 1996. Apicidin: A novel antiprotozoal agent that inhibits parasite histone deacetylase. Proceedings of the National Academy of Sciences USA 93: 13143-13147.
4. DUBEY, J. P., D. E. HILL, J. L. JONES, A. W. HIGHTOWER, E. KIRKLAND, J. M. ROBERTS, P. L. MARCET, T. LEHMANN, M. C. B. VIANNA, K. MISKA, C. SREEKUMAR, O. C. H. KWOK, S. K. SHEN, AND H. R. GAMBLE. 2005. Prevalence of viable Toxoplasma gondii in beef, chicken, and pork from retail meat stores in the United States: Risk assessment to consumers. Journal of Parasitology 91: 1082-1093.
5. _, AND D. S. LINDSAY. 2004. Biology of Toxoplasma gondii in cats and other animals. In World class parasites, Vol. 9, D. S. Lindsay and L. M. Weiss (eds.). Kluwer Academic, Boston, Massachusetts, p. 1-19.
6. FRICKER-HIDAIGO, H., J. P. BRION, M. DURAND, O. CHAVANON, M. P. BRENIER-PINCHART, AND H. PELLOUX. 2005. Disseminated toxoplasmosis with pulmonary involvement after heart transplantation. Transplantation and Infectious Disease 7: 38-40.
7. FURUMAI, R., Y. KOMATSU, N. NISHINO, S. KHOCHBIN, M. YOSHIDA, AND S. HORINOUCHI. 2001. Potent histone deacetylase inhibitors built from trichostatin A and cyclic tetrapeptide antibiotics including trapoxin. Proceedings of the National Academy of Sciences USA 98: 87-92.
8. GABRIELLI, B. G. 2006. Histone deacetylase inhibitors deliver their therapeutic benefit by targeting the cell cycle. In American Association for Cancer Research Education Book. Available: http://www. educationbook.aacrjournals.org. p. 318-321.
9. GLASER, K. B., J. LI, M. J. STAVER, R. Q. WEI, D. H. ALBERT, AND S. K. DAVIDSON. 2003. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochemical and Biophysical Research Communications 310: 529-536.
10. GURVICH, N., O. M. TSYGANKOVA, J. L. MEINKOTH, AND P. S. KLEIN. 2004. Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Research 64: 1079-1086.
11. HU, E., E. DUL, C. M. SUNG, Z. CHEN, R. KIRKPATRICK, G. F. ZHANG, K. JOHANSON, R. LIU, A. LAGO, G. HOFMANN, R. MACARRON, M. DE LOS FRAILES, P. PEREZ, J. KRAWIEC, J. WINKLER, AND M. JAVE. 2003. Identification of novel isoform-selective inhibitors within class I histone deacetylases. Journal of Pharmacology and Experimental Therapeutics 307: 720-728.
12. ITO, A., N. NISHINO, AND M. YOSHIDA. 2006. HDAC inhibitors: Discovery, development, and clinical impacts. In Histone deacetylases: Transcriptional regulation and other cellular functions, E. Verdin (ed.). Humana Press, Totowa, New Jersey, p. 271-297.
13. JONES-BRANDO, L., E. F. TORREY, AND R. YOLKEN. 2003. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophrenia Research 62: 237-244.
14. KEEN, J. C., L. YAN, K. M. MACK, C. PETTIT, D. SMITH, D. SHARMA, AND N. E. DAVIDSON. 2003. A novel histone deacetylase inhibitor: Scriptaid, enhances expression of functional estrogen receptor α (ER) in ER negative human breast cancer cells in combination with 5-aza 2′-deoxycytidine. Breast Cancer Research and Treatment 81: 177-186.
15. KELLY, W. K., O. A. O'CONNOR, L. M. KRUG, J. H. CHIAO, M. HEANEY, T. CURLEY, B. MACGREGORE-CORTELLI, W. TONG, J. P. SECRIST, L. SCHWARTZ, S. RICHARDSON, E. CHU, S. OLGAC, P. A. MARKS, H. SCHER, AND V. M. RICHON. 2005. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. Journal of Clinical Oncology 23: 3923-3931.
16. KHAN, F. J. T., C.-L. QIN, AND K. KIM. 2002. Cyclin-dependent kinase TPK2 is a critical cell cycle regulator in Toxoplasma gondii. Molecular Microbiology 45: 321-332.
17. KISSINGER, J. C., B. GAJRIA, L. LI, T. PAULSEN, AND D. S. ROOS. 2003. ToxoDB: accessing the Toxoplasma gondii genome. Nucleic Acids Research 31: 234-236.
18. KOMATSU, N., N. KAWAMATA, S. TAKEUCHI, D. YIN, W. CHIEN, C. W. MILLER, AND H. P. KOEFFLER. 2006. SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncology Reports 15: 187-191.
19. KWON, P., M. HSU, D. COHEN, AND P. ATADJA. 2006. HDAC inhibitors: An emerging anticancer therapeutic strategy. In Histone deacetylases, transcriptional regulation and other cellular functions, E. Verdin (ed.). Humana Press, Totowa, New Jersey, p. 315-332.
20. MARTIROSYAN A., S. LEONARD, X. SHI, B. GRIFFITH, P. GANNETT, AND J. STROBL. 2006. Actions of a histone deacetylase inhibitor NSC3853 (5-nitroso-8-quinolinol) links reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. Journal of Pharmacology and Experimental Therapeutics 317: 546-552.
21. MCALLISTER, M. M. 2005. A decade of discoveries in veterinary protozoology changes our concept of "subclinical" toxoplasmosis. Veterinary Parasitology 132: 241-247.
22. MORADEI, O., C. R. MAROUN, I. PAQUIN, AND A. VAISBURG. 2005. Histone deacetylase inhibitors: Latest developments, trends and prospects. Current Medical Chemistry of Anti-Cancer Agents 5: 529-560.
23. MURRAY, H. W., AND Z. A. COHN. 1979. Macrophage oxygen-dependent antimicrobial activity. I. Susceptibility of Toxoplasma gondii to oxygen intermediates. Journal of Experimental Medicine 150: 938-949.
24. O'CONNOR, O. A., M. L. HEANEY, L. SCHWARTZ, S. RICHARDSON, R. WILLIM, B. MACGREGOR- CORTELLI, T. CURLY, C. MOSKOWITZ, C. PORTLOCK, S. HORWITZ, A. D. ZELENETZ, S. FRANKEL, V. RICHON, P. MARKS, AND W. K. KELLY. 2006. Clinical experience with intravenous and oral formulations of the novel histone deacetylase inhibitor suberoylanilide hydroxamic acid in patients with advanced hematologic malignancies. Journal of Clinical Oncology 24: 166-173.
25. RADKE, J. R., B. STRIEPEN, M. N. GUERINI, M. E. JEROME, D. S. ROOS, AND M. W. WHITE. 2001. Defining the cell cycle for the tachyzoite stage of Toxoplasma gondii. Molecular and Biochemical Parasitology 115: 165-175.
26. RICHON, V. M., S. EMILIANI, E. VERDIN, Y. WEBB, R. BRESLOW, R. A. RIFKIND, AND P. A. MARKS. 1998. A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proceedings of the National Academy of Sciences USA 95: 3003-3007.
27. SAKSOUK, N., M. M. BHATTI, S. KIEFFER, A. T. SMITH, K. MUSSET, J. GARIN, W. J. SULLIVAN, JR., M.-F. CESBRON-DELAUW, AND M.-A. HAKIMI. 2005. Histone-modifying complexes regulate gene expression pertinent to the differentiation of the protozoan parasite Toxoplasma gondii. Molecular and Cellular Biology 25: 10301-10314.
28. SAUVE, A. A., C. WOLBERGER, V. L. SCHRAMM, AND J. D. BOEKE. 2006. The biochemistry of sirtuins. Annual Review of Biochemistry 75: 435-465.
29. SETO, E. 2006. The biology of HDAC3. In Histone deacetylases: Transcriptional regulation and other cellular functions, E. Verdin (ed.). Humana Press, Totowa, New Jersey, p. 61-86.
30. SONNEMANN, J., J. GANGE, S. PILZ, C. STOZER, R. OHLINGER, A. BELAU, G. LORENZ, AND J. F. BECK. 2006. Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients. BMC Cancer 6: 183 (Epub).
31. SU, G. H., T. A. SOHN, B. RYU, AND S. E. KERN. 2000. A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library. Cancer Research 60: 3137-3142.
32. SULLIVAN, W. J., JR., AND M. A. HAKIMI. 2006. Histone mediated gene activation in Toxoplasma gondii. Molecular and Biochemical Parasitology 148: 109-116.
33. SUZUKI, T., AND N. MIYATE. 2005. Non-hydroxamate histone deacetylase inhibitors. Current Medical Chemistry 12: 2867-2880.
34. TAKADA, Y., A. GILLENWATER, H. ICHIKAWA, AND B. B. AGGARWAL. 2006. Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor kappaB activation. Journal of Biological Chemistry 281: 5612-5622.
35. TAKAI, N., T. UEDA, M. NISHIDA, K. NASU, AND H. NARAHAR. 2006. A novel histone deacetylase inhibitor, scriptaid, induces growth inhibition, cell cycle arrest and apoptosis in human endometrial cancer and ovarian cancer cells. International Journal of Molecular Medicine 17: 323-329.
36. VERDIN, E. 2006. Histone deacetylases: Transcriptional regulation and other cellular functions. Humana Press, Totowa, New Jersey.
37. WILSON, A. J., D. S. BYUN, N. POPOVA, L. B. MURRAY, K. L'ITALLEN, Y. SOWA, D. ARANGO, A. VELCICH, L. H. AUGENLICHT, AND J. M. MARIADASON. 2006. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. Journal of Biological Chemistry 281: 13548-13558.
38. YANG, W. M., S. C. TSAI, Y. D. WEN, G. FEJER, AND E. SETO. 2002. Functional domains of histone deacetylase-3. Journal of Biological Chemistry 277: 9447-9454.
39. ZHANG, C., V. RICHON, X. NI, R. TALPUR, AND M. DUVIC. 2005. Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: Relevance to mechanism of therapeutic action. Journal of Investigative Dermatology 125: 1045-1052.